Hoffman Alvary advised one or both parties in 75+ major law firm mergers.
Hoffman Alvary has served as advisor to 64 of the AmLaw 100.
Nearly 80 AmLaw 100 and 200 firms participate in The Hoffman Alvary Survey on Law Firm Economics.
Principals in the IP and Valuations areas have testified as expert witnesses in over 60 trials.
Hoffman Alvary works for 2/3 of the largest IP practices in the U.S.
Hoffman Alvary has modified over 70 partner compensation systems in major law firms.
Hoffman Alvary has advised over 25 major law firms on reducing their unfunded partner retirement obligations.
Hoffman Alvary has developed partner succession programs for 30 major law firms.

Hoffman Alvary is a consulting firm providing independent advisory services to law firms, their clients and other institutions worldwide.  The firm's Principals focus in three main areas of practice.

Law Firm Consulting providing a broad range of strategic and management consulting services to law firms prominent nationally and in their local markets.  Hoffman Alvary brings years of experience and an in-depth knowledge of the issues facing the managers of law firms in today's challenging environment.

Intellectual Property and Valuation Consulting assisting companies and their counsel in a broad range of areas including expert witness testimony, licensing matters, valuations and general consulting.

Our Professional Disputes practice provides services in connection with disputes involving professional services firms and issues related to legal and other malpractice claims.

Hoffman Alvary provides customized solutions to the complex financial and strategic issues faced by our clients.  The firm's reputation is built on our strategic thinking, efficiency, accuracy and discretion.




Law Firm Consulting's First Report: Hoffman Alvary polled major US law firms on their 2016 results and 2017 outlook.  The published First Report describing outcomes, views for 2017 and market observations can be accessed here

Valuation Insights: Our commentaries on current valuation issues in biotechnology and life sciences 

September 2017 - Zombie Biotechs: Contributing to the high cost of capital in the industry

May 2017 - Immunomedics Update: Terminated deal clears the way to unlock previously unrealized value

April 2017 - Dispute over Immunomedics’ $2 billion deal raises key issues for the valuation of late-stage therapeutics

October 2016 - CAR-T immunotherapies face linked clinical fortunes and potential IP risks 

July 2016 - Valuations of gene therapy programs ignore the risks posed by high treatment prices